Trump nominates Chris Klomp as HHS second-in-command

Trump Nominates Chris Klomp as HHS Second-in-Command

Trump nominates Chris Klomp as HHS second – On Thursday, President Donald Trump announced the appointment of Chris Klomp, currently serving as Medicare director and a seasoned health care executive, to the position of deputy secretary of the U.S. Department of Health and Human Services (HHS). This decision marks a significant shift in the administration’s leadership structure, as Klomp will now assume a pivotal role in overseeing the agency’s operational framework and shaping regulatory policies. His elevation to this position comes at a time when the HHS is seeking to streamline its efforts under a new leadership strategy, as noted by sources familiar with the internal discussions.

Leadership Transition and Key Responsibilities

The deputy secretary role is critical, placing Klomp in a position of influence just below Secretary Robert F. Kennedy Jr., who has been a central figure in the administration’s health care agenda. Klomp’s appointment is expected to solidify the team’s alignment with Trump’s priorities, particularly in advancing cost-cutting initiatives and expanding the scope of the TrumpRx program. As the second-highest-ranking official, he will play a key role in coordinating the agency’s responses to policy challenges and ensuring the implementation of the administration’s health care reforms.

Klomp’s selection follows a series of leadership changes within the HHS, including the departure of Jim O’Neill in February. The shakeup aimed to realign the agency’s focus toward reducing healthcare costs and promoting the TrumpRx initiative, which seeks to negotiate lower drug prices for Medicare beneficiaries. Klomp, who has been instrumental in these efforts since joining the administration in April 2025, was initially tasked with managing HHS operations and advising Kennedy. His expertise in navigating the complexities of the Medicare program has positioned him as a central figure in the administration’s push for policy innovation.

“HHS is a massive and complex organization, but Chris knows exactly how to run it,” Trump stated in a post on Truth Social. The president emphasized that Klomp’s appointment reflects his ability to lead with clarity and efficiency, despite the challenges of managing a sprawling federal agency.

Trump also highlighted Klomp’s collaborative approach, stating that the decision was made collectively with Kennedy and Centers for Medicare & Medicaid Services Administrator Dr. Mehmet Oz. “You don’t know his name as much as some of the others, but he’s a real star of the group,” the president remarked during a White House event in April, underscoring Klomp’s behind-the-scenes contributions to recent healthcare deals.

Following the nomination, Klomp will need to undergo Senate confirmation, adding his name to a list of federal health appointees awaiting hearings before the Senate Health, Education, Labor and Pensions Committee. The confirmation process is a key step in securing his role, as it involves scrutiny of his qualifications and alignment with the administration’s goals. While the Senate has been busy with other appointments, Klomp’s nomination is seen as a strategic move to bolster the HHS’s administrative capabilities.

Policy Impact and Strategic Contributions

Klomp’s tenure as Medicare director has been marked by his active involvement in negotiations with pharmaceutical companies and the development of the most-favored nations plan. This initiative, designed to lower prescription drug costs for seniors, has become a cornerstone of the administration’s health care strategy. His ability to mediate deals and drive policy outcomes has earned him recognition as a key architect of these reforms, even though his name may not be as widely known as that of other officials.

Since taking on the Medicare director role, Klomp has played a central part in the administration’s efforts to broker favorable terms with drug manufacturers. His work on the TrumpRx program has been particularly notable, as it aims to create a system where Medicare beneficiaries receive the lowest possible drug prices. This focus on affordability has been a recurring theme in Trump’s health care rhetoric, and Klomp’s appointment is viewed as a way to reinforce that commitment.

Additionally, Klomp has been involved in the search for new leadership within the HHS, including candidates for the U.S. Centers for Disease Control and Prevention (CDC) and the surgeon general’s office. In April, Trump nominated public health veteran Dr. Erica Schwartz for CDC director and Fox News contributor Dr. Nicole Saphier for the surgeon general role, both of whom are still awaiting Senate confirmation. Klomp’s role in these selections suggests his growing influence in shaping the agency’s future direction.

His experience in the private sector as a health care executive has provided him with a unique perspective on both regulatory and operational challenges. This background, combined with his hands-on involvement in Medicare initiatives, has made him a valuable asset to the administration. However, his transition to a federal role also highlights the importance of public-private partnerships in achieving the Trump administration’s health care objectives.

Broader Implications for HHS Leadership

The appointment of Klomp as deputy secretary comes amid a broader reorganization of the HHS, which has been reshaped to emphasize efficiency and cost control. The previous leadership changes, including the departure of Dr. Marty Makary as FDA commissioner in May, underscore the administration’s focus on streamlining processes and ensuring that federal agencies operate in alignment with its core principles. Klomp’s role in this reorganization has been critical, as he has helped integrate the TrumpRx program into the HHS’s strategic framework.

With the HHS leadership now in flux, Klomp’s appointment is expected to provide stability and continuity. His close relationship with Kennedy, who has been overseeing the agency’s operations for several months, is seen as a key factor in his selection. The two have worked closely to refine the administration’s messaging and ensure that policies are implemented effectively. Klomp’s ability to translate this messaging into actionable strategies has been a significant asset, according to sources within the HHS.

As the new deputy secretary, Klomp will also be responsible for managing the agency’s internal operations, ensuring that its various departments function cohesively. This includes overseeing the implementation of new policies, coordinating with other federal agencies, and maintaining the HHS’s public-facing initiatives. His experience in the private sector, where he has managed large-scale healthcare operations, is believed to be a major advantage in this role.

The confirmation process for Klomp will be an important test of the administration’s ability to secure support for its policies. While the Senate has been cautious in recent months, the president’s endorsement and Klomp’s track record in the HHS suggest a strong likelihood of approval. His appointment is seen as a way to consolidate the administration’s vision for healthcare reform and ensure that its initiatives are carried forward with determination.

As the HHS continues to adapt to the evolving healthcare landscape, Klomp’s role as deputy secretary will be crucial in maintaining momentum. His leadership is expected to bridge the gap between the administration’s policy goals and the practical execution of those policies. The combination of his expertise in Medicare and his ability to work collaboratively with key officials like Kennedy and Oz positions him as a strong candidate to guide the agency through its next phase of development.